At the heart of the matter: The endocannabinoid system in cardiovascular function and dysfunction

Trends in Pharmacological Sciences

Volumn 33, Issue 6, 2012, Pages 331-340

  Montecucco, Fabrizio ^a   Di Marzo, Vincenzo ^b  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b CNR   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N MORPHOLINO 1H PYRAZOLE 3 CARBOXAMIDE; 1 DEOXY 3 (1,1 DIMETHYLBUTYL) DELTA8 TETRAHYDROCANNABINOL; 2 ARACHIDONOYLGLYCEROL; AM 3506; ANANDAMIDE; CALCIUM CHANNEL; CANNABIDIOL; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; DOXORUBICIN; ENDOCANNABINOID; FATTY ACID AMIDASE INHIBITOR; N ARACHIDONOYLDOPAMINE; N PALMITOYL ETHENOLAMINE; PALMIDROL; POTASSIUM CHANNEL; RIMONABANT; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR 1;

ANTIOXIDANT ACTIVITY; ATHEROGENESIS; ATHEROSCLEROSIS; CARDIODEPRESSION; CARDIOMETABOLIC RISK; CARDIOMYOPATHY; CARDIOTOXICITY; CARDIOVASCULAR FUNCTION; CHEMICAL STRUCTURE; CIRRHOTIC CARDIOMYOPATHY; DIABETIC CARDIOMYOPATHY; DRUG EFFECT; DRUG INDUCED DISEASE; DRUG MECHANISM; HEART ARRHYTHMIA; HEART DISEASE; HEART FUNCTION; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERTENSION; HYPOTENSION; LIVER CIRRHOSIS; MOLECULAR DYNAMICS; NONHUMAN; OBESITY; PRIORITY JOURNAL; RECEPTOR BLOCKING; REGULATORY MECHANISM; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; VASODILATATION;

ANIMALS; ANTIOXIDANTS; BLOOD PRESSURE; CANNABIS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR SYSTEM; ENDOCANNABINOIDS; HEART RATE; HUMANS; MICE; OXIDATIVE STRESS; PLAQUE, ATHEROSCLEROTIC; PSYCHOTROPIC DRUGS; RATS; RECEPTOR, CANNABINOID, CB1; RECEPTOR, CANNABINOID, CB2; SIGNAL TRANSDUCTION; TETRAHYDROCANNABINOL;

EID: 84861916493     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2012.03.002     Document Type: Review

References (91)

1. Di Marzo, V. (2009) The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol. Res. 60, 77-84
2. Di Marzo, V. (2008) Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov. 7, 438-455
3. Jones, R.T. (2002) Cardiovascular system effects of marijuana. J. Clin. Pharmacol. 42, 58S-63S
4. Lake, K.D. et al. (1997) Cannabinoid-induced hypotension and bradycardia in rats mediated by CB1-like cannabinoid receptors. J. Pharmacol. Exp. Ther. 281, 1030-1037 (Pubitemid 27258357)
5. Wagner, J.A. et al. (1998) Cardiovascular actions of cannabinoids and their generation during shock. J. Mol. Med. (Berl.) 76, 824-836 (Pubitemid 28518708)
6. Pacher, P. et al. (2005) Hemodynamic profile, responsiveness to anandamide, and baroreflex sensitivity of mice lacking fatty acid amide hydrolase. Am. J. Physiol. Heart Circ. Physiol. 289, H533-H541 (Pubitemid 41129366)
7. Malinowska, B. et al. (2001) Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn Schmiedebergs Arch. Pharmacol. 364, 562-569 (Pubitemid 33145097)
8. Zygmunt, P.M. et al. (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400, 452-457 (Pubitemid 29361798)
9. Jordt, S.E. et al. (2004) Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427, 260-265
10. Hiley, C.R. and Ford, W.R. (2004) Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biol. Rev. Camb. Philos. Soc. 79, 187-205 (Pubitemid 38282051)
11. Wagner, J.A. et al. (2001) Hemodynamic effects of cannabinoids: coronary and cerebral vasodilation mediated by cannabinoid CB1 receptors. Eur. J. Pharmacol. 423, 203-210 (Pubitemid 32614159)
12. Járai, Z. et al. (1999) Cannabinoid-induced mesenteric vasodilation through an endothelial site distinct from CB1 or CB2 receptors. Proc. Natl. Acad. Sci. U.S.A. 96, 14136-14141
13. Wang, Y. et al. (2007) Endocannabinoid regulates blood pressure via activation of the transient receptor potential vanilloid type 1 in Wistar rats fed a high-salt diet. J. Pharmacol. Exp. Ther. 321, 763-769 (Pubitemid 46624495)
14. Domenicali, M. et al. (2005) Increased anandamide induced relaxation in mesenteric arteries of cirrhotic rats: role of cannabinoid and vanilloid receptors. Gut 54, 522-527 (Pubitemid 40395505)
15. Ray, A.M. et al. (2003) Capsazepine protects against neuronal injury caused by oxygen glucose deprivation by inhibiting Ih. J. Neurosci. 23, 10146-10153 (Pubitemid 37392563)
16. Ledent, C. et al. (1999) Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science 283, 401-404
17. 2+-dependent potassium channels in in vitro anandamide-mediated mesenteric vasorelaxation in rats with biliary cirrhosis. Liver Int. 27, 1045-1055
18. Járai, Z. et al. (2000) Cardiovascular effects of 2-arachidonoyl glycerol in anesthetized mice. Hypertension 35, 679-684 (Pubitemid 30108168)
19. 2+-induced relaxation of rat mesenteric arteries. Am. J. Physiol. Heart Circ. Physiol. 294, H2363-H2370
20. O'Sullivan, S.E. et al. (2004) Characterisation of the vasorelaxant properties of the novel endocannabinoid N-arachidonoyl-dopamine (NADA). Br. J. Pharmacol. 141, 803-812 (Pubitemid 38446181)
21. Pacher, P. et al. (2005) Cardiovascular pharmacology of cannabinoids. Handb. Exp. Pharmacol. 168, 599-625
22. Godlewski, G. et al. (2010) Inhibitor of fatty acid amide hydrolase normalizes cardiovascular function in hypertension without adverse metabolic effects. Chem. Biol. 17, 1256-1266
23. Milman, G. et al. (2006) N-Arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc. Natl. Acad. Sci. U.S.A. 103, 2428-2433 (Pubitemid 43271686)
24. Bradshaw, H.B. et al. (2009) The endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathways. BMC Biochem. 10, 14
25. Parmar, N. and Ho, W.S. (2010) N-Arachidonoyl glycine, an endogenous lipid that acts as a vasorelaxant via nitric oxide and large conductance calcium-activated potassium channels. Br. J. Pharmacol. 160, 594-603
26. Poblete, I.M. et al. (2005) Anandamide elicits an acute release of nitric oxide through endothelial TRPV1 receptor activation in the rat arterial mesenteric bed. J. Physiol. 568, 539-551 (Pubitemid 41555456)
27. McHugh, D. et al. (2010) N-Arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptor. BMC Neurosci. 11, 44
28. Ho, W.S. et al. (2008) 'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors. Br. J. Pharmacol. 155, 837-846
29. Wheal, A.J. et al. (2012) Hydrogen peroxide as a mediator of vasorelaxation evoked by N-oleoylethanolamine and anandamide in rat small mesenteric arteries. Eur. J. Pharmacol. 674, 384-390
30. Hiley, C.R. and Kaup, S.S. (2007) GPR55 and the vascular receptors for cannabinoids. Br. J. Pharmacol. 152, 559-561 (Pubitemid 350034976)
31. Johns, D.G. et al. (2007) The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol. 152, 825-831 (Pubitemid 350034974)
32. Pacher, P. et al. (2004) Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J. Physiol. 558, 647-657 (Pubitemid 39117608)
33. Bátkai, S. et al. (2007) Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J. 21, 1788-1800 (Pubitemid 46855625)
34. Mukhopadhyay, P. et al. (2007) Pharmacological inhibition of CB1 cannabinoid receptor protects against doxorubicin-induced cardiotoxicity. J. Am. Coll. Cardiol. 50, 528-536 (Pubitemid 47126779)
35. Lépicier, P. et al. (2003) Endocannabinoids protect the rat isolated heart against ischaemia. Br. J. Pharmacol. 139, 805-815 (Pubitemid 36819608)
36. Lo Verme, J. et al. (2005) The nuclear receptor peroxisome proliferator-activated receptor-alpha mediates the anti-inflammatory actions of palmitoylethanolamide. Mol. Pharmacol. 67, 15-19 (Pubitemid 40069962)
37. Di Marzo, V. et al. (2001) Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 358, 249-255 (Pubitemid 32778120)
38. Lagneux, C. and Lamontagne, D. (2001) Involvement of cannabinoids in the cardioprotection induced by lipopolysaccharide. Br. J. Pharmacol. 132, 793-796 (Pubitemid 32193634)
39. Joyeux, M. et al. (2002) Endocannabinoids are implicated in the infarct size-reducing effect conferred by heat stress preconditioning in isolated rat hearts. Cardiovasc. Res. 55, 619-625 (Pubitemid 34874956)
40. Montecucco, F. et al. (2009) CB2 cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/reperfusion. J. Mol. Cell Cardiol. 46, 612-620
41. Defer, N. et al. (2009) The cannabinoid receptor type 2 promotes cardiac myocyte and fibroblast survival and protects against ischemia/reperfusion- induced cardiomyopathy. FASEB J. 23, 2120-2130
42. Rajesh, M. et al. (2007) Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am. J. Physiol. Heart Circ. Physiol. 293, H610-H619 (Pubitemid 47105122)
43. Rajesh, M. et al. (2010) Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J. Am. Coll. Cardiol. 56, 2115-2125
44. Durst, R. et al. (2007) Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am. J. Physiol. Heart Circ. Physiol. 293, H3602-H3607 (Pubitemid 350230905)
45. Bisogno, T. et al. (2001) Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide. Br. J. Pharmacol. 134, 845-852 (Pubitemid 33016156)
46. Montecucco, F. et al. (2010) Single administration of the CXC chemokine-binding protein Evasin-3 during ischemia prevents myocardial reperfusion injury in mice. Arterioscler. Thromb. Vasc. Biol. 30, 1371-1377
47. Walsh, S.K. et al. (2010) Acute administration of cannabidiol in vivo suppresses ischaemia-induced cardiac arrhythmias and reduces infarct size when given at reperfusion. Br. J. Pharmacol. 160, 1234-1242
48. Amorós, I. et al. (2010) Endocannabinoids and cannabinoid analogues block human cardiac Kv4.3 channels in a receptor-independent manner. J. Mol. Cell Cardiol. 48, 201-210
49. Korantzopoulos, P. et al. (2008) Atrial fibrillation and marijuana smoking. Int. J. Clin. Pract. 62, 308-313
50. Singal, P.K. and Iliskovic, N. (1998) Doxorubicin-induced cardiomyopathy. N. Engl. J. Med. 339, 900-905 (Pubitemid 28446849)
51. Zhang, Y.W. et al. (2009) Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch. Immunol. Ther. Exp. (Warsz) 57, 435-445
52. Hydock, D.S. et al. (2009) Anandamide preserves cardiac function and geometry in an acute doxorubicin cardiotoxicity rat model. J. Cardiovasc. Pharmacol. Ther. 14, 59-67
53. Mukhopadhyay, P. et al. (2011) Fatty acid amide hydrolase is a key regulator of endocannabinoid-induced myocardial tissue injury. Free Radic. Biol. Med. 50, 179-195
54. Mukhopadhyay, P. et al. (2010) CB1 cannabinoid receptors promote oxidative stress and cell death in murine models of doxorubicin-induced cardiomyopathy and in human cardiomyocytes. Cardiovasc. Res. 85, 773-784
55. Theocharidou, E. et al. (2012) Cardiac dysfunction in cirrhosis - does adrenal function play a role? A hypothesis. Liver Int. DOI: 10.1111/j.1478-3231. 2011.02751.x
56. Bá tkai, S. et al. (2001) Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat. Med. 7, 827-832
57. Bá tkai, S. et al. (2007) Endocannabinoids acting at CB1 receptors mediate the cardiac contractile dysfunction in vivo in cirrhotic rats. Am. J. Physiol. Heart Circ. Physiol. 293, H1689-H1695
58. Pacher, P. et al. (2005) Cirrhotic cardiomyopathy: an endocannabinoid connection? Br. J. Pharmacol. 146, 313-314 (Pubitemid 41486672)
59. Yang, Y.Y. et al. (2010) Mechanisms of TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice: interaction between TNFalpha and endocannabinoids. J. Hepatol. 53, 298-306
60. Guimond, A. et al. (2007) Quantitative ultrasonic tissue characterization as a new tool for continuous monitoring of chronic liver remodelling in mice. Liver Int. 27, 854-864 (Pubitemid 47062053)
61. Moezi, L. et al. (2006) Anandamide mediates hyperdynamic circulation in cirrhotic rats via CB1 and VR1 receptors. Br. J. Pharmacol. 149, 898-908 (Pubitemid 44851714)
62. Pi-Sunyer, F.X. et al. (2006) Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. J. Am. Med. Assoc. 295, 761-775 (Pubitemid 43244304)
63. Van Gaal, L.F. et al. (2005) Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 365, 1389-1397 (Pubitemid 40523733)
64. Nissen, S.E. et al. (2008) Effect of rimonabant on progression of atherosclerosis in patients with abdominal obesity and coronary artery disease: the STRADIVARIUS randomized controlled trial. J. Am. Med. Assoc. 299, 1547-1560 (Pubitemid 351482794)
65. Di Marzo, V. and Després, J.P. (2009) CB1 antagonists for obesity - what lessons have we learned from rimonabant? Nat. Rev. Endocrinol. 5, 633-638
66. Quarta, C. et al. (2011) Energy balance regulation by endocannabinoids at central and peripheral levels. Trends Mol. Med. 17, 518-526
67. Di Marzo, V. et al. (2011) Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb. Exp. Pharmacol. 203, 75-104
68. Montecucco, F. et al. (2009) Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis. Atherosclerosis 205, 433-441
69. Dol-Gleizes, F. et al. (2009) Rimonabant, a selective cannabinoid CB1 receptor antagonist, inhibits atherosclerosis in LDL receptor-deficient mice. Arterioscler. Thromb. Vasc. Biol. 29, 12-18
70. Tiyerili, V. et al. (2010) CB1 receptor inhibition leads to decreased vascular AT1 receptor expression, inhibition of oxidative stress and improved endothelial function. Basic Res. Cardiol. 105, 465-477
71. Di Marzo, V. et al. (2009) Changes in plasma endocannabinoid levels in viscerally obese men following a 1 year lifestyle modification programme and waist circumference reduction: associations with changes in metabolic risk factors. Diabetologia 52, 213-217
72. Quercioli, A. et al. (2011) Elevated endocannabinoid plasma levels are associated with coronary circulatory dysfunction in obesity. Eur. Heart J. 32, 1369-1378
73. Sugamura, K. et al. (2009) Activated endocannabinoid system in coronary artery disease and antiinflammatory effects of cannabinoid 1 receptor blockade on macrophages. Circulation 119, 28-36
74. Liu, J. et al. (2000) Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem. J. 346, 835-840 (Pubitemid 30171048)
75. Rajesh, M. et al. (2010) Cannabinoid-1 receptor activation induces reactive oxygen species-dependent and -independent mitogen-activated protein kinase activation and cell death in human coronary artery endothelial cells. Br. J. Pharmacol. 160, 688-700
76. Han, K.H. et al. (2009) CB1 and CB2 cannabinoid receptors differentially regulate the production of reactive oxygen species by macrophages. Cardiovasc. Res. 84, 378-386
77. Rajesh, M. et al. (2008) Cannabinoid CB1 receptor inhibition decreases vascular smooth muscle migration and proliferation. Biochem. Biophys. Res. Commun. 377, 1248-1252
78. Curcio, A. et al. (2011) Mechanisms of smooth muscle cell proliferation and endothelial regeneration after vascular injury and stenting: approach to therapy. Circ. J. 75, 1287-1296
79. El-Remessy, A.B. et al. (2011) Cannabinoid 1 receptor activation contributes to vascular inflammation and cell death in a mouse model of diabetic retinopathy and a human retinal cell line. Diabetologia 54, 1567-1578
80. Rajesh, M. et al. (2012) Cannabinoid 1 receptor promotes cardiac dysfunction, oxidative stress, inflammation, and fibrosis in diabetic cardiomyopathy. Diabetes 61, 716-727
81. Horvá th, B. et al. (2012) The endocannabinoid system and plantderived cannabinoids in diabetes and diabetic complications. Am. J. Pathol. 180, 432-442
82. Maeda, N. et al. (2009) Increased serum anandamide level at ruptured plaque site in patients with acute myocardial infarction. Fundam. Clin. Pharmacol. 23, 351-357
83. Montecucco, F. et al. (2008) CB2 cannabinoid receptor agonist JWH-015 modulates human monocyte migration through defined intracellular signaling pathways. Am. J. Physiol. Heart Circ. Physiol. 294, H1145-H1155 (Pubitemid 351468709)
84. Rajesh, M. et al. (2007) CB2-receptor stimulation attenuates TNF-alpha-induced human endothelial cell activation, transendothelial migration of monocytes, and monocyte-endothelial adhesion. Am. J. Physiol. Heart Circ. Physiol. 293, H2210-H2218 (Pubitemid 47605864)
85. Hoyer, F.F. et al. (2011) Atheroprotection via cannabinoid receptor-2 is mediated by circulating and vascular cells in vivo. J. Mol. Cell Cardiol. 51, 1007-1014
86. Steffens, S. et al. (2005) Low dose oral cannabinoid therapy reduces progression of atherosclerosis in mice. Nature 434, 782-786 (Pubitemid 44739523)
87. Netherland, C.D. et al. (2010) Cannabinoid receptor type 2 (CB2) deficiency alters atherosclerotic lesion formation in hyperlipidemic Ldlr-null mice. Atherosclerosis 213, 102-108
88. Delsing, D.J. et al. (2011) Cannabinoid receptor 2 deficiency in haematopoietic cells aggravates early atherosclerosis in LDL receptor deficient mice. Open Cardiovasc. Med. J. 5, 15-21
89. Rajesh, M. et al. (2008) CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br. J. Pharmacol. 153, 347-357
90. Molica, F. et al. (2012) The cannabinoid receptor CB2 protects against balloon-induced neointima formation. Am. J. Physiol. Heart Circ. Physiol. 312, H1064-H1074
91. Montecucco, F. et al. (2011) The activation of the cannabinoid receptor type 2 (CB2) reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques. Eur. Heart J. DOI: 10.1093/eurheartj/ehr449